chr12-76346147-T-C
Variant summary
Our verdict is Uncertain significance. Variant got 4 ACMG points: 4P and 0B. PM2PP3PP5
The NM_024685.4(BBS10):āc.1838A>Gā(p.Tyr613Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000472 in 1,610,182 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024685.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS10 | NM_024685.4 | c.1838A>G | p.Tyr613Cys | missense_variant | 2/2 | ENST00000650064.2 | NP_078961.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS10 | ENST00000650064.2 | c.1838A>G | p.Tyr613Cys | missense_variant | 2/2 | NM_024685.4 | ENSP00000497413 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152158Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000323 AC: 8AN: 247514Hom.: 0 AF XY: 0.00000747 AC XY: 1AN XY: 133878
GnomAD4 exome AF: 0.0000501 AC: 73AN: 1458024Hom.: 0 Cov.: 32 AF XY: 0.0000441 AC XY: 32AN XY: 725228
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152158Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74334
ClinVar
Submissions by phenotype
not provided Pathogenic:3Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 08, 2024 | Published functional studies demonstrate a damaging effect (PMID: 20498079); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31964843, 16582908, 20498079, 36312387) - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 11, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Bardet-Biedl syndrome Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jun 06, 2023 | Variant summary: BBS10 c.1838A>G (p.Tyr613Cys) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 247514 control chromosomes (gnomAD). c.1838A>G has been reported in the literature in compound heterozygous individual(s) affected with Bardet-Biedl Syndrome who carried a pathogenic variant in trans (Stoetzel_2006). At least one publication reported experimental evidence evaluating an impact on protein function, and demonstrated that this variant results in a null allele in a zebrafish model (Zaghloul_2010). The following publications have been ascertained in the context of this evaluation (PMID: 20498079, 16582908). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant a pathogenic, likely pathogenic, or VUS. Based on the evidence outlined above, the variant was classified as likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 613 of the BBS10 protein (p.Tyr613Cys). This variant is present in population databases (rs575957641, gnomAD 0.005%). This missense change has been observed in individual(s) with clinical features of Bardet-Biedl syndrome (PMID: 16582908; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 195379). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BBS10 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BBS10 function (PMID: 20498079). For these reasons, this variant has been classified as Pathogenic. - |
Bardet-Biedl syndrome 10 Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 19, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 02, 2018 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at